RxDoctor Payments Data

Julie Cordero, APRN

Family · Palmdale, CANPI 1033781687

Payments from drug & device makers

$357in general payments, 2019–2025

Across 16 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$81
  • Lilly USA, LLC$61
  • Boehringer Ingelheim$48
  • AstraZeneca$40
  • GSK$30
  • Merck$26
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$357 in reported general payments places this provider in the 55th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$3,111
Medicare patients
11
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$85,379
JardianceEmpagliflozin39$46,657
Metformin Er GastricMetformin Hcl18$38,511
EliquisApixaban22$20,850
FarxigaDapagliflozin Propanediol13$16,904
Breo ElliptaFluticasone/Vilanterol38$16,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,104
Diclofenac Sodium31$10,724
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate28$9,162
JanuviaSitagliptin Phosphate13$8,431
LinzessLinaclotide12$7,818
Amlodipine-AtorvastatinAmlodipine/Atorvastatin45$7,643
Spiriva RespimatTiotropium Bromide11$5,839
Albuterol Sulfate HfaAlbuterol Sulfate162$4,038
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$85,37986 claims
Boehringer IngelheimJardiance, Spiriva Respimat$48$52,49750 claims
GSKBreo Ellipta, Trelegy Ellipta$30$32,71663 claims
AstraZenecaFarxiga, Symbicort$40$19,36824 claims
MerckJanuvia$26$8,43113 claims
AbbVieLinzess$81$7,81812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,634 family providers in California.

Other family in Palmdale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →